End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
36.43 CNY | -1.22% | +3.79% | -40.39% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.39% | 12.07B | B | ||
-3.35% | 88.91B | A- | ||
+4.08% | 41.25B | A- | ||
-15.09% | 31.99B | B- | ||
+50.70% | 24.73B | A | ||
-15.13% | 15.54B | C | ||
-8.63% | 12.05B | D+ | ||
-14.78% | 12.02B | B- | ||
+6.22% | 8.84B | B+ | ||
-5.15% | 8.3B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300122 Stock
- Ratings Chongqing Zhifei Biological Products Co., Ltd.